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Abstract. Aim: To examine the antiproliferative and
apoptotic effects of resveratrol on imatinib-sensitive and
imatinib-resistant K562 chronic myeloid leukemia cells.
Materials and Methods: Antiproliferative effects of
resveratrol were determined by the 3-Bis[2-methoxy-4-
nitro-5-sulphophenyl]-2H-tetrazolium-5-carboxanilide
inner salt (XTT) cell proliferation assay. Apoptotic effects
of resveratrol on sensitive K562 and resistant K562/IMA-3
cells were determined through changes in caspase-3
activity, loss of mitochondrial membrane potential (MMP),
and apoptosis by annexin V-(FITC). Results: The
concentrations of resveratrol that inhibited cell growth by
50% (IC50) were calculated as 85 and 122 μM for K562
and K562/IMA-3 cells, respectively. There were 1.91-, 7.42-
and 14.73-fold increases in loss of MMP in K562 cells
treated with 10, 50, and 100 μM resveratrol, respectively.
The same concentrations of resveratrol resulted in 2.21-,
3.30- and 7.65-fold increases in loss of MMP in K562/IMA-
3 cells. Caspase-3 activity increased 1.04-, 2.77- and 4.8-
fold in K562 and 1.02-, 1.41- and 3.46-fold in K562/IMA-
3 cells in response to the same concentrations of
resveratrol, respectively. Apoptosis was induced in 58.7%-
and 43.3% of K562 and K562/IMA-3 cells, respectively, in
response to 100 μM resveratrol. Conclusion: Taken together
these results may suggest potential use of resveratrol in
CML, as well as in patients with primary and/or acquired
resistance to imatinib. 
Chronic myeloid leukemia (CML), a hematological disease,
arises from the reciprocal translocation between the break-
point cluster (BCR) gene on chromosome 22 and the
Abelson leukemia virus oncogene (ABL) gene on
chromosome 9 (1). This translocation generates the
Philadelphia (Ph) chromosome encoding BCR-ABL fusion
protein which has constitutively activated tyrosine kinase
activity. This protein has an ATP-binding pocket and a
substrate-binding site (2). When ATP binds to the ATP-
binding pocket of this protein, ATP constitutively
phosphorylates its substrate, therefore, BCR-ABL becomes
active. BCR-ABL induces many signaling pathways
contributing to cell survival and causing the disruption of
genetic stability (3). In the clinic, tyrosine kinase inhibitors
are generally used for CML therapy. Imatinib mesylate, a
first-generation tyrosine kinase inhibitor, binds to the ATP-
binding pocket of BCR-ABL, preventing the phosphorylation
of the substrate, and then also activation of BCR-ABL.
Nowadays, imatinib is used for first-line therapy in CML due
to its great efficacy (4). However, the therapeutic efficacy of
imatinib is reduced by the emergence of resistance towards
this drug (5). Point mutations in the kinase domain of BCR-
ABL, activation of membrane transporters, overexpression of
BCR-ABL, aberrant ceramide metabolism, and the presence
of CML stem cells in a quiescent state are the main
molecular mechanisms underlying drug resistance in CML
(6, 7). To overcome this resistance, more effective tyrosine
kinase inhibitors are being developed (8), but drug resistance
and adverse effects of new agents are still important
problems. Therefore, natural products have been investigated
due to their potential in cancer prevention and treatment (9).
Resveratrol (3,5,4’-trans-trihydroxystilbene), one of the most
important natural products, is produced by numerous plants,
especially by red grapes, in order to protect themselves from
detrimental environmental conditions (10, 11). Resveratrol has
been reported to have the potential to inhibit cancer initiation,
promotion, and progression (12). It has also anti-metastatic,
anti-inflammatory, chemopreventive, radiosensitizer, and even
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chemosensitizer effects (13-15). Through binding directly to
DNA or RNA, resveratrol protects DNA from mutagens (12).
Furthermore, resveratrol can induce apoptosis via inhibiting
DNA topoisomerase II, nuclear factor kappa B (NF-κB) or
signal transducer and activator of transcription 3 (STAT3)
pathways, and by repressing the expressions of anti-apoptotic
genes such as B-cell lymphoma-extra large (BCL-XL), B-cell
lymphoma 2 (BCL-2), and X-linked inhibitor of apoptosis
protein (XIAP) (12, 16).
The aim of this study was to examine the antiproliferative
effects of resveratrol on imatinib-sensitive and imatinib-
resistant, Philadelphia-positive K562 CML cells we
developed in our laboratory over three years.
Materials and Methods
Chemicals. Resveratrol was obtained from Sigma Aldrich (St. Louis,
MO, USA). The stock solution of resveratrol was dissolved in
dimethylsulfoxide (DMSO) at a concentration of 10 M, stored at
–20˚C, and diluted in cell culture medium. Penicillin-streptomycin,
RPMI 1640, and fetal bovine serum were obtained from Invitrogen
(Paisley, UK).
Cell lines and culture conditions. Human K562 CML cells were
obtained from the German Collection of Microorganisms and Cell
Cultures (Braunschweig, Germany). K562 cells were maintained in
RPMI 1640 growth medium containing 10% fetal bovine serum and
1% penicillin-streptomycin at 37˚C in 5% CO2. K562 cells grown in
RPMI 1640 were exposed to increasing concentrations of imatinib,
starting with 50 nM. At the end of this process, we obtained cells
resistant to 3 μM imatinib and named them K562/IMA-3 cells. 
Measurement of cell growth by 3-bis[2-methoxy-4-nitro-5-
sulphophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT)
assay. The resveratrol concentration inhibiting cell growth by 50%
(IC50) was determined by XTT cell proliferation assay. In brief,
2×104 cells/200 μl/well were seeded into 96-well plates containing
100 μl of the growth medium in the absence or presence of
increasing concentrations of resveratrol, and were then incubated at
37˚C with 5% CO2. After a 72 h incubation period, cells were
treated with 50 μl XTT for 4 h. Then, plates were read at 492 nm
wavelength by an ELISA reader (Thermo Electron Corporation
Multiskan Spectrum, Vantaa, Finland). Finally, the IC50 value of
resveratrol was calculated according to the cell proliferation plots. 
Evaluation of apoptosis. 
Determination of the changes in caspase-3 activity: Changes in
caspase-3 activity of the cells, as an important sign of apoptosis,
were determined by caspase-3 colorimetric assay kit as described
elsewhere (BioVision, Edmonton, AB, Canada) (17). This assay is
based on spectrophotometric detection of the chromophore 
p-nitroanilide (pNA) after cleavage from the labelled substrate
acetyl-Asp-Glu-Val-Asp (DEVD)-pNA which is a specific substrate
for caspase-3 enzyme. Briefly, the cells (1×106 cells/2 ml/well)
induced to undergo apoptosis by treatment with resveratrol, were
collected by centrifugation at 800 ×g for 10 min. The cells were
lysed by adding 50 μl of chilled cell lysis buffer and incubated on
ice for 10 min before centrifugation at 10,000 ×g for 1 min. Since
the proteins were in supernatant, the upper part of the mixture was
transferred to new Eppendorf tubes and the reaction mixture was
prepared in 96-well plates by adding 50 μl of 2× reaction buffer
[containing 10 mM dithiothreitol (DTT)], 50 μl of sample, and 
5 μl of DEVD-pNA substrate, and the plates were incubated for 2
h at 37˚C with %5 CO2. At the end of this period of time, the plate
was read at 405 nm wavelength by an ELISA reader (Thermo
Electron Corporation Multiskan Spectrum). The absorbance values
were normalized to protein concentrations determined by the
Bradford assay as decribed (7). 
Detection of loss of mitochondrial membrane potential (MMP):
The loss of MMP is an indicator of apoptosis and was detected by
JC-1 mitochondrial membrane potential detection kit as described
elsewhere (Cayman Chemicals, Ann Arbor, MI, USA) (18).
Imatinib-resistant and sensitive K562 cells (5×105) were seeded
into 96-well plates in 100 μl growth medium. These cells were
treated with different concentrations of resveratrol and incubated
for 72 h at 37˚C with 5% CO2. After 72 h, cells were treated with
10 μl JC-1 staining solution and incubated for 20 min in 5% CO2.
The cells were then collected and centrifuged for 5 min at 400 ×g.
The supernatant was removed and cell pellet was washed with
1×phosphate buffered saline (PBS) before centrifugation at 400 ×g
for 5 min. This step was repeated twice. Finally, 100 μl assay
buffer was added to the cells. The aggregate red forms accumulated
in the inner mitochondria have absorption/emission maxima of
585/590 nm and the monomeric green forms released into the
cytoplasm due the loss of the MMP have absorption/emission
maxima of 510/527 nm. The plate was read at these wavelengths
by fluorescence ELISA reader (Thermo Varioskan Spectrum).
Green/red (510/585) absorption values were calculated in order to
determine the changes in MMP. 
Detection of early apoptosis by Annexin V-Fluorescein
isothiocyanate (FITC): K562/IMA-3 and sensitive K562 (1×106)
cells were seeded onto 6-well plates and treated with different
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Figure 1. Cytotoxic effects of resveratrol on K562/IMA-3 cells.
Cytotoxicity was determined by the Bis[2-methoxy-4-nitro-5-
sulphophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT) cell
proliferation assay in a 72 h culture. The XTT assays were performed
using triplicate samples in at least three independent experiments.
Values are the arithmetic means of triplicates. The error bars represent
the standard deviation. 
concentrations of resveratrol. Cells were incubated for 72 h with
5% CO2. Then the cells were centrifuged at 800 ×g for 5 min.
Supernatants were removed and binding buffer was added to the
pellets. Cells were treated with 5 μl of FITC and 5 μl of
propidium iodide (PI). The mixture was incubated for 15 min in
the dark. The samples were then analyzed for AnnexinV-FITC
binding by flow cytometry (Ex=488 nm; Em=530 nm) using
FITC signal detector and PI staining emission signal detector.
H2O2, FITC and PI were also added to cells and were used as
positive control.
Results
Cellular growth assessment via XTT cell proliferation assay.
Our previous findings demonstrated that K562/IMA-3 cells
were around 100-fold more resistant to imatinib as compared
to sensitive K562 cells (17). Cytotoxic effects of resveratrol
on K562/IMA-3 and sensitive K562 cells were determined
by XTT cell proliferation assay. We previously determined
the IC50 value of resveratrol for K562 cells as being 85 μM
(18), while that for K562/IMA-3 was calculated from cell
proliferation plots and found to be 122 μM (Figure 1). These
results demonstrated that K562/IMA-3 cells were only 1.4-
fold more resistant to resveratrol than were K562 cells.
Resveratrol reduced cell proliferation of both cell types in a
dose dependent manner.
Resveratrol increases caspase-3 activity in a dose dependent
manner in both K562 and K562/IMA-3 cells. In order to
examine the changes in caspase-3 activity in response to
resveratrol, K562 and K562/IMA-3 cells were treated with
different concentrations of resveratrol for 72 h. The results
demonstrated that caspase-3 activity in K562 cells treated with
10, 50 and 100 μM resveratrol was 1.09-, 2.77- and 4.88-fold,
respectively, as compared to the untreated control group
(Figure 2A). On the other hand, the same concentrations of
resveratrol increased caspase-3 activity in K562/IMA3 cells to
1.02-, 1.41- and 3.46-fold that of the control, respectively
(Figure 2B). Resveratrol increased caspase-3 activity in a dose
dependent manner with no significant changes in K562 and
K562/IMA-3 cells. 
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Figure 2. Changes in caspase-3 activity in response to resveratrol in
K562 (A) and K562/IMA-3 (B) cells. Values are the arithmetic means of
three independent experiments. The error bars represent the standard
deviations.
Figure 3. Changes in cytoplasmic/mitochondrial JC-1 in K562 (A) and
K562/IMA-3 (B) cells in response to resveratrol. Values are the
arithmetic means of three independent experiments. The error bars
represent the standard deviations.
Resveratrol induces loss of MMP in both K562 and
K562/IMA-3 cells in a dose-dependent manner. In order to
confirm the findings of caspase-3 activity, the same
concentrations of resveratrol were applied to K562 and
K562/IMA-3 cells and the loss of MMP was determined. The
results revealed that loss of MMP was 1.91-, 7.42-, and 14.73-
fold in K562 cells treated with 10, 50, and 100 μM resveratrol,
respectively, as compared to untreated controls (Figure 3A).
The same concentrations of resveratrol led to a loss of MMP
of 2.21-, 3.30-, and 7.65-fold in K562/IMA-3 cells,
respectively, as compared to untreated controls (Figure 3B).
Resveratrol induces apoptosis of both K562 and K562/IMA-
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Figure 4. Changes in populations of apoptotic and necrotic K562 (A, B) and K562/IMA-3 cells (A, C) in response to resveratrol.
3 cells in a dose-dependent manner. In order to confirm
changes in caspase-3 activity and loss of MMP in response
to resveratrol, we examined the changes in the apoptotic cell
population in K562 and K562/IMA-3 cells exposed to
increasing concentrations of resveratrol by Annexin-V
apoptosis assay and flow cytometry. The results
demonstrated that 9.3% and 8.3% of the K562 and
K562/IMA3 cell populations were in apoptosis, respectively,
in response to 10 μM resveratrol (Figure 4). On the other
hand, 100 μM resveratrol induced apoptosis in 37% and 28%
of K562 and K562/IMA-3 cells, respectively (Figure 4).
Resveratrol increased apoptotic cell population in a dose
dependent manner in both cell lines but there was no
significant change in the apoptotic populations of K562 and
K562/IMA-3 cells.
Discussion 
Imatinib mesylate is a first-generation tyrosine kinase
inhibitor suppressing the activity of BCR-ABL fusion
protein, the initiator of CML. It is accepted as the gold
standard for treatment of CML patients. Imatinib not only
targets the BCR-ABL fusion protein but also the tyrosine-
protein kinase kit (c-KIT) and the platelet-derived growth
factor receptor (PDGFR) (19, 20). Imatinib is a competitive
inhibitor which specifically recognizes and binds to the ATP
binding site of the protein, and prevents phosphorylation of
downstream substrates of the oncogenic protein (21). The
most important problem in the treatment of CML by
imatinib, as observed for other different types of cancer, is
the development of resistance or intolerance to imatinib (6,
22). Unfortunately, resistance is still an important problem
for the treatment of CML with novel agents, nilotinib and
dasatinib, which are more effective than imatinib (23).
Recent studies focused on the reversal of the resistance and
the investigation of natural products that may have potential
to be used as a supplementary to anticancer agents. In this
study, we aimed at examining the anticancer potential of
resveratrol, a plant-derived phytochemical, on both imatinib-
sensitive and -resistant K562 cells. 
Different groups showed that resveratrol induces
apoptosis, and has anti-metastatic, anti-inflammatory,
cardioprotective, chemopreventive and radiosensitizer
effects (13-15). More importantly, resveratrol inhibits
initiation and progression of different types of cancer (12).
Resveratrol triggers apoptosis in cancer cells through both
intrinsic and extrinsic pathways. Gledhill et al. showed that
resveratrol inhibits F0F1 ATP synthase, which is involved
in cellular ATP synthesis, and induces apoptosis via
mitochondrial dysfunction (24). While resveratrol reduces
expression of breast cancer resistance protein (BCRP) in
breast cancer (25), treatment of prostate cancer cells with
resveratrol increases the expression of Bcl-2 associated X
(BAX), Bcl-2 associated death promoter (BAD), BH3
domain only death agonist (BID), and Bcl-2 homologous
antagonist/killer (BAK) apoptotic genes and of p53, the
guardian of the genome (26). Our group recently showed
that resveratrol triggers apoptosis through up-regulating
longevity assurance (LASS) genes that generate apoptotic
ceramides and by down-regulating sphingosine kinase-1 and
glucosylceramide synthase genes that convert apoptotic
ceramides to antiapoptotic sphingosine-1-phosphate and
glucosylceramide lipids, respectively, in acute myeloid
leukemia (18) and CML cells (27). Furthermore, Ragione et
al. demonstrated that resveratrol inhibits carcinogenesis and
induces differentiation of CML and acute myeloid leukemia
cells (28, 29).
Our results demonstrated that resveratrol has
antiproliferative and apoptotic effects on K562 CML cells.
More importantly, we have also shown for the first time that
resveratrol has significant apoptotic and antiproliferative
effects on K562/IMA-3 cells that are ~100-fold more
resistant to imatinib as compared to their parental sensitive
counterparts (17). 
Taken together, the results of this study indicate that
resveratrol may have therapeutic potential and suggest that
consumption of resveratrol-containing products may help
CML treatment of both imatinib-sensitive and -resistant cases. 
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